Fig. 2

Pre- and post-treatment patient-related outcome-based cluster analysis. Cluster analysis of study participants by patient reported outcomes (PRO) at baseline and at week 24 (exposed to secukinumab 300 mg). Colors show Z scores with blue indicating the respective patient-related outcome being better than the mean and red indicating the parameter being lower than mean. Baseline clustering by disease type (very early disease vs. established psoriatic arthritis) is lost after secukinumab treatment and replaced by clusters related to the amount of physical and mental disease burden. Left: Baseline cluster showing accumulation of very early disease patients in the upper cluster with milder PROs, while patients with established disease accumulate in the lower cluster with more severe impact of disease. Right: 24 week clusters showing redistribution of very early and established disease among 4 clusters: top: high disease burden in physical and mental PROs, upper: moderate disease burden in physical and mental PROs, lower: low disease burden in physical and mental PROs, bottom: low disease burden in physical and moderate in mental PROs; DLQI, Dermatology Life Quality Index; PsA, psoriatic arthritis; PsAID, Psoriatic Arthritis Impact of Disease; VAS, visual analog scale